Project Grant R01HL176717
Award Date
1/16/25
Completion Date
11/30/28
Dollars Obligated
$481K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), totals $827,682 and is effective from July 29, 2024 through June 30, 2029. The award aims to develop comprehensive imaging approaches to characterize lung perfusion and guide treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition that is a leading cause of death from COVID-19. The project will leverage...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at the University of Illinois to investigate the role of the CARMIL1 protein in regulating pulmonary endothelial cell barrier function. The $495,159 award, with a project period from September 1, 2024 to May 31, 2029, will employ biochemical, imaging, and functional studies to characterize how CARMIL1 affects actin cytoskeleton...
This $1,147,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The award aims to address key unanswered questions about the functional immune response and pathogen drivers underlying distinct "hyperinflammatory" and "hypoinflammatory" phenotypes observed in these critical...
This $775,992 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in resolving acute lung injury and pneumonia. The project aims to determine how Treg glucocorticoid receptor signaling affects Treg function and the...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The award supports research to investigate indole metabolites as novel danger signals that activate regulated cell death pathways and innate immune responses in lung epithelial cells, and their potential role in the pathogenesis of acute respiratory distress syndrome (ARDS). The research aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $704,795 to Baylor College of Medicine to develop a cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The research aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines (IL-1RA, IL-10) for local, sustained delivery to the lungs via airway and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth). The 7-year award, running from March 1, 2025 to December 31, 2031, will support UTHealth's "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The program encompasses three...
This $148,568 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research on the role of pleural mesothelial cells in lung injury, repair, and regeneration. The awardee, Mayo Clinic, will conduct a combination of lineage-tracing experiments and genomic analysis to investigate the signaling and functional roles of pleural mesothelial cells in the context of lung injury, fibrosis, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $161,240 in funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), over the period of August 1, 2024 to July 31, 2029. The objective of this research is to define endothelial S1PR1-dependent pathways that promote re-alveolarization and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the mechanisms by which tissue-resident lymphocytes suppress alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). The research aims to uncover therapeutic approaches to attenuate the frequent...